Clinical Trials Logo

Clinical Trial Summary

The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.


Clinical Trial Description

Patients with refractory hypertension, defined as uncontrolled office blood pressure despite use of 5 or more antihypertensive agents, including a thiazide diuretic and spironolactone. After withdrawal from other centrally-acting agents if needed, enrolled patients will be randomized to open-label reserpine 0.1 mg daily for 4 weeks. Twenty-four hour ambulatory blood pressure monitoring will be done at baseline, after the initial 4-week treatment period. All other antihypertensive medications will remain unchanged during the 4-week treatment period. The primary endpoint will be change in 24-hr ambulatory systolic blood pressure. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03223272
Study type Interventional
Source University of Alabama at Birmingham
Contact
Status Completed
Phase Phase 2
Start date July 23, 2015
Completion date January 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Completed NCT00812695 - Effects of Continuous Positive Airway Pressure (CPAP) in Patients With Resistant Hypertension and Obstructive Sleep Apnea (OSA) Phase 3
Terminated NCT00899977 - TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension Phase 1/Phase 2
Completed NCT00746902 - Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome Phase 3
Completed NCT01656096 - Renal Sympathetic Denervation in Mild Refractory Hypertension Phase 4